Publications by authors named "A Ia Danilov"
Characterization of tumor epigenetic aberrations is integral to understanding the mechanisms of tumorigenesis and provide diagnostic, prognostic, and predictive information of high clinical relevance. Among the different tumor-associated epigenetic signatures, 5 methyl-cytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are the two most well-characterized DNA methylation alterations linked to cancer pathogenesis. 5hmC has a tissue-specific distribution and its abundance is subjected to changes in tumor DNA, making it a promising biomarker.
View Article and Find Full Text PDFThe anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1) contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models.
View Article and Find Full Text PDFThe B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, including chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B cell lymphoma and Waldenström macroglobulinaemia. Bruton tyrosine kinase (BTK) is a key node mediating signal transduction downstream of the BCR. The advent of BTK inhibitors has revolutionized the treatment landscape of B cell malignancies, with these agents often replacing highly intensive and toxic chemoimmunotherapy regimens as the standard of care.
View Article and Find Full Text PDF[Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia].
Zh Nevrol Psikhiatr Im S S Korsakova
September 2024
Objective: To study the efficacy and safety of the drug Picamilon with various therapy regimens in patients with stage II chronic cerebral ischemia (CCI).
Material And Methods: An open cohort clinical study involved 50 patients diagnosed with stage II CCI aged 51 to 69 years (average age 62.2±8.
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia.
Expert Rev Anticancer Ther
October 2024
Article Synopsis
- High-risk factors traditionally predicted poor outcomes for CLL patients, but the use of BTK inhibitors has improved survival rates even for those with these high-risk features.
- Continuous treatment with BTK inhibitors has positively affected survival, while finite-duration therapies like venetoclax combinations haven't shown the same results.
- Ongoing research and new treatments emphasize the importance of understanding prognostic factors to guide therapy decisions and encourage participation in clinical trials for patients with high-risk CLL.